Form 4 for ALZN Alzamend Neuro, Inc.
Accepted 2023-05-02 00:00:00 ET · period of report 2023-04-28 · accession 0001214659-23-006373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-02 | 2023-04-28 | ALZN | Jackman Stephan | CEO, Dir | P - Purchase | $0.54 | +37.0K | 45.5K | +435% | +$20.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-28 | P | A | 37,000 | $0.54 | 45,500 | D | — | — | (F1) The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.5405. The range of purchase prices on the transaction date was $0.5398 to $0.5499 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. |